Central pontine myelinolysis and locked-IN syndrome associated with tacrolimus after pediatric heart transplantation

Pediatr Transplant. 2023 May;27(3):e14474. doi: 10.1111/petr.14474. Epub 2023 Jan 30.

Abstract

Background: Locked-in syndrome represents the most severe form of central pontine myelinolysis and varies in presentation from asymptomatic to fully developed locked-in-syndrome characterized by the combination of quadriplegia, loss of the ability to communicate except through the use of the eyes, and an inability to follow commands.

Methods: We report a 10-year-old boy who developed a severe case of locked-in syndrome after heart transplantation.

Results: Patient had a spontaneous recovery, treated with supportive treatment and the improvement was detected with cessation of calcineurin inhibitor therapy by substituting with an mTOR inhibitor (sirolimus). No cases of locked-in syndrome post-heart transplant in pediatrics cases have been documented in the literature.

Conclusion: Physicians should recognize a rapid progression of central pontine myelinolysis and locked-in syndrome in the context of heart transplant and although several factors likely contributed to this outcome, adjustment of immunosuppression including by substituting tacrolimus with sirolimus could be effective.

Keywords: central pontine myelinolysis; heart transplant.

Publication types

  • Case Reports

MeSH terms

  • Child
  • Heart Transplantation* / adverse effects
  • Humans
  • Locked-In Syndrome*
  • Magnetic Resonance Imaging
  • Male
  • Myelinolysis, Central Pontine*
  • Sirolimus
  • Tacrolimus / adverse effects

Substances

  • Tacrolimus
  • Sirolimus